The authors describe the ways in which manufacturers can mitigate the risks related to the integrity of recombinant transgenes expressed in CHO cells.
Christopher Frye
Advertisement
Articles by Christopher Frye
Advertisement
Latest Updated Articles
A Risk-Based Genetic Characterization Strategy for Recombinant CHO Cell Lines Used for Clinical and Commercial ApplicationsPublished: March 1st 2016 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Everything to Know About Cell and Gene Therapy in 2025
2
Biologics, Obesity, China Top Financial Trends Reshaping Pharma R&D in J.P. Morgan Report
3
Overcoming Funding Challenges and Maintaining Optimism in CGTs (Part 1)
4
CGT Innovations: The Three-Pronged Strategy for Industry Growth (Part 2)
5
